CVS Health Corporation (NYSE: CVS) unveiled its financial performance for the first quarter ending March 31, 2024, showcasing robust revenue growth alongside strategic adjustments to its annual guidance. First Quarter…
Amgen (NASDAQ: AMGN) has announced the unveiling of groundbreaking respiratory research at the American Thoracic Society (ATS) 2024 International Conference, scheduled from May 12 to May 22 in San Diego.…
Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the close of the U.S. financial markets. The announcement will be followed by a…
Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) have received approval from the U.S. Food and Drug Administration (FDA) for the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab…
AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA…
AstraZeneca’s Truqap (capivasertib) combined with Faslodex (fulvestrant) has received a positive recommendation for approval in the European Union (EU) for treating adult patients with locally advanced or metastatic breast cancer…
The DESTINY-Breast06 Phase III trial yielded encouraging results, demonstrating the effectiveness of Enhertu (trastuzumab deruxtecan) in improving progression-free survival (PFS) significantly and meaningfully compared to standard chemotherapy. This positive outcome…
AbbVie Initiates Construction of State-of-the-Art Research Hub, “LUnA,” in Germany with €150 Million Investment AbbVie has commenced the construction of its new central research building, dubbed “LUnA” (LUdwighafens neue Arbeitswelt),…
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has revealed findings from its Phase 3 trial, STRIDE-10, assessing V116, the company’s advanced 21-valent pneumococcal…
Recognizing the Stealthy Signs of Bladder Cancer Identifying bladder cancer in its early stages can be challenging, as its symptoms often mimic those of benign conditions like urinary tract infections…
Eli Lilly and Company (NYSE: LLY) unveiled its financial performance for the first quarter of 2024 today. David A. Ricks, Lilly’s chair and CEO, commented on the company’s robust year-over-year…
Alentis Therapeutics, a cutting-edge biotech firm dedicated to combatting organ fibrosis and Claudin-1 positive tumors, has just announced the appointment of Dr. Alberto Toso as its Chief Scientific Officer, effective…